Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Palliative Radiotherapy in Thoracic Tumours
NCT02587455Phase 1Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Jun 2016
- Primary completion
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoints: Toxicity Rate of Dose Limiting Toxicities (DLTs) Assessed by CTCAEv4 and Maximum Tolerated Dose (MTD) of Pembrolizumab That Can be Safely Combined With Radiotherapy (RT). Started Jun 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02587455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02587455.